CEFAZOLIN FOR INJECTION 10 G — DIN 02108135
CEFAZOLIN (CEFAZOLIN SODIUM) : 10 G · TEVA CANADA LIMITED · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is CEFAZOLIN FOR INJECTION?
CEFAZOLIN FOR INJECTION 10 G contains CEFAZOLIN (CEFAZOLIN SODIUM) : 10 G. It is listed in the Health Canada Drug Product Database under DIN 02108135, held by TEVA CANADA LIMITED, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 27-Sep-2022. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is CEFAZOLIN FOR INJECTION used for?
Treatment of respiratory tract, urinary tract, skin and soft tissue, bone and joint infections, septicemia, and endocarditis caused by susceptible organisms. Perioperative prophylaxis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Cefazolin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Cefazolin, across 34 DINs, of which 15 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FRESENIUS KABI CANADA LTD | 6 | 3 | CEFAZOLIN FOR INJECTION, CEFAZOLIN FOR INJECTION, USP | Sourceable in Canada |
| HIKMA CANADA LIMITED | 3 | 3 | CEFAZOLIN FOR INJECTION | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 3 | 3 | CEFAZOLIN FOR INJECTION USP | Sourceable in Canada |
| STERIMAX INC | 3 | 3 | CEFAZOLIN SODIUM FOR INJECTION BP | Sourceable in Canada |
| TEVA CANADA LIMITED | 3 | 2 | CEFAZOLIN FOR INJECTION | Sourceable in Canada |
| BAXTER CORPORATION | 1 | 1 | CEFAZOLIN IN DEXTROSE INJECTION, USP | Sourceable in Canada |
| PFIZER CANADA ULC | 3 | 0 | CEFAZOLIN FOR INJECTION USP | No marketed DIN |
| PHARMACEUTICAL PARTNERS OF CANADA INC | 3 | 0 | KEFZOL | No marketed DIN |
| SMITHKLINE BEECHAM PHARMA DIVISION OF SMITHKLINE BEECHAM INC | 3 | 0 | ANCEF INJ PWS 10GM/VIAL USP, ANCEF INJ PWS 1GM/VIAL USP, ANCEF INJ PWS 500MG/VIAL USP | No marketed DIN |
| TEVA PHARMACEUTICAL INDUSTRIES LTD | 3 | 0 | STERILE CEFAZOLIN SODIUM | No marketed DIN |
| ELI LILLY CANADA INC | 2 | 0 | KEFZOL ADD-VANTAGE INJ 1GM/VIAL, KEFZOL ADD-VANTAGE INJ 500MG/VIAL | No marketed DIN |
| NOVOPHARM LIMITED | 1 | 0 | CEFAZOLIN FOR INJECTION USP | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 10 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 500 mg and 1 g single dose vials; 10 g Pharmacy Bulk Vials. |
| Storage | Reconstituted solutions should be used within 24 hours at room temperature or 72 hours under refrigeration. Pharmacy Bulk Vial contents used within 8 hours. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Cefazolin |
|---|---|
| ATC code | J01DB04 |
| AHFS class | 08:12.06.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02108135 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2108135 |
| Brand name | CEFAZOLIN FOR INJECTION |
| Generic / active ingredient | CEFAZOLIN (CEFAZOLIN SODIUM) : 10 G |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | J01DB04 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01DB |
| Current status | CANCELLED POST MARKET |
| Status date | 27-Sep-2022 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administered IV or IM. Adults: 250 mg to 1 g every 6-12 hours depending on infection type. Perioperative prophylaxis: 1 g IV/IM 30-60 mins pre-surgery. Dosage adjustment required for renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to cefazolin sodium, any ingredient in the formulation, or to the cephalosporin group of antibiotics.
Warnings and precautions
Potential cross-allergenicity with penicillins. Risk of Clostridioides difficile-associated disease. Severe cutaneous adverse reactions (SCAR) reported. Seizures may occur in renal impairment.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
15 of 34 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CEFAZOLIN FOR INJECTION | 10 G | POWDER FOR SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02437120 |
| CEFAZOLIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02437104 |
| CEFAZOLIN FOR INJECTION | 500 MG | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | 02108119 |
| CEFAZOLIN FOR INJECTION | 1 G | POWDER FOR SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02437112 |
| CEFAZOLIN FOR INJECTION | 1 G | POWDER FOR SOLUTION | TEVA CANADA LIMITED | MARKETED | 02108127 |
| CEFAZOLIN FOR INJECTION USP | 1 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02308959 |
| CEFAZOLIN FOR INJECTION USP | 500 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02308932 |
| CEFAZOLIN FOR INJECTION USP | 10 G | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02308967 |
| CEFAZOLIN FOR INJECTION, USP | 100 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02401029 |
| CEFAZOLIN FOR INJECTION, USP | 1 G | POWDER FOR SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02237138 |
2 · Same class — other molecules in ATC J01DB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Cefalexin | APO-CEPHALEX · ASN-CEPHALEXIN · AURO-CEPHALEXIN · CEPHALEXIN · +25 more | 47 | 23 | Yes |
| Cefazolin | ANCEF INJ PWS 10GM/VIAL USP · ANCEF INJ PWS 1GM/VIAL USP · ANCEF INJ PWS 500MG/VIAL USP · CEFAZOLIN FOR INJECTION · +8 more | 34 | 15 | Yes |
| Cefadroxil | APO-CEFADROXIL · CEFADROXIL · DURICEF · JAMP CEFADROXIL · +2 more | 6 | 3 | Yes |
| Cefalotin | CEPORACIN · KEFLIN ADD-VANTAGE INJ 1GM/VIAL · KEFLIN NEUTRAL INJ 1GM · KEFLIN NEUTRAL INJ 2GM/VIAL | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01DD | Cefixime · Cefotaxime · Cefpodoxime · Ceftazidime · Ceftizoxime · +1 more | 96 | 25 |
| J01DH | Doripenem · Ertapenem · Imipenem And Cilastatin · Meropenem · Meropenem And Vaborbactam | 51 | 24 |
| J01DC | Cefaclor · Cefamandole · Cefotetan · Cefoxitin · Cefprozil · +1 more | 135 | 18 |
| J01DE | Cefepime | 10 | 3 |
| J01DF | Aztreonam | 1 | 1 |
| J01DI | Ceftobiprole Medocaril · Ceftolozane And Beta-Lactamase Inhibitor | 2 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CEFAZOLIN FOR INJECTION called?
The same molecule, Cefazolin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| CEFAZOLIN NORIDEM | Latin | Czechia |
| AZEPO | Latin | Czechia |
| VULMIZOLIN | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Cefazolin called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Cefazolin, published to help those searches reach this page.
| Language | Cefazolin |
|---|---|
| Arabic العربية | سيفازولين |
| Chinese (Simplified) 简体中文 | 头孢唑林 |
| Russian Русский | Цефазолин |
| Spanish Español | Cefazolina |
| Portuguese Português | Cefazolina |
| German Deutsch | Cefazolin |
| Japanese 日本語 | セファゾリン |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.